Virolfi

Valganciclovir is a synthetic antiviral prodrug of ganciclovir, a guanine nucleoside analog, administered orally for the treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).[1] It is also indicated for the prevention of CMV disease in high-risk adult and pediatric patients following kidney, heart, or kidney-pancreas transplantation.[1] Developed by F. Hoffmann-La Roche Ltd. and marketed under the brand name Valcyte, valganciclovir received initial U.S. Food and Drug Administration approval on March 29, 2001.[2] Upon ingestion, valganciclovir undergoes rapid hydrolysis in the intestinal wall and liver to ganciclovir, achieving approximately 60% oral bioavailability, which surpasses that of oral ganciclovir alone.[3] The active metabolite, ganciclovir, is selectively phosphorylated by CMV-encoded thymidine kinase in infected cells, forming ganciclovir triphosphate that competitively inhibits viral DNA polymerase and incorporates into viral DNA, terminating chain elongation.[4] This mechanism confers activity primarily against herpesviruses, especially CMV, with limited impact on host cell replication due to lower affinity for cellular DNA polymerase.[5] Valganciclovir's clinical utility stems from its convenience over intravenous ganciclovir, enabling outpatient management of CMV infections, though it carries risks of significant adverse effects including neutropenia, anemia, and thrombocytopenia due to bone marrow suppr